Baglietto et al. have further emphasized the uniqueness of the MSH6 mutation in endometrial carcinoma: women carrying MSH6 mutations are more prone to developing EC than CRC: the EC morbidity is 26 times higher for MSH6 mutation carriers, whereas the incidence of CRC is only 8-fold higher, and the incidence of other LS-associated cancers is only 6-fold higher3. Here, MSH6 is linked to endometrial carcinoma.